Preprint · CC-BY
via OpenAlex
Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis
Zhen Yu, Shuai Tong, Can Zhang, Yue Yu Bai, Zhijing An, Chang Xu, Fang Wang, Yi Hu, Qinghui Zhuang, Xiaosong Zhong
Research Square · 2022 · ▲ 3 citations
Abstract
Abstract Chimeric antigen receptor (CAR)-modified T cells targeting antigens expressed on tumor cells have exhibited significant antitumor effects on several types of hematological malignancies, including acute myeloid leukemia, lymphoma, B cell maturation antigen, and CD19-positive acute lymphoblastic leukemia. However, several drawbacks, particularly the poor persistence, limit the use of CAR-T cell-based therapy. Nicotinamide mononucleotide (NMN), the precursor of nicotinamide adenine dinucleotide (NAD+), has been shown to reverse age-related complications and slow the aging rate by enhancing NAD+ levels in the body. However, whether NMN treatment could enhance the longevity and persistence of CAR-T cells and improve their antitumor efficacy is still unclear. In this study, we observed that NMN treatment limited differentiation and significantly increased stem cell–like memory (Tscm) and stem cell–like memory (Tcm) in CD19 CAR-T cells. In addition, both telomerase length and proliferation ability were increased, whereas apoptosis was reduced after NMN treatment of CD19 CAR-T cells. High-throughput sequencing data indicated that NMN treatment upregulated Sirt1 expression in CD19 CAR-T cells and downregulated genes downstream of Sirt1, such as NF-κB, TP53, and Bax. Animal experiments showed that NMN treated CAR-T cells exerted great antitumor efficacy in human xenografted mouse models. In conclusion, NMN enhances the efficacy and longevity of CD19 CAR-T cells via the NAD+–Sirt1 axis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.21203/rs.3.rs-1483519/v1
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Yu, Z., Tong, S., Zhang, C., Bai, Y.Y., An, Z., Xu, C., Wang, F., Hu, Y., Zhuang, Q., & Zhong, X. (2022). Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis. <em>Research Square</em>. https://doi.org/10.21203/rs.3.rs-1483519/v1
Vancouver
Yu Z, Tong S, Zhang C, Bai YY, An Z, Xu C, et al. Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis. Research Square. 2022. doi:10.21203/rs.3.rs-1483519/v1.
BibTeX
@unpublished{zhen2022Nicoti,
title = {Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis},
author = {Zhen Yu and Shuai Tong and Can Zhang and Yue Yu Bai and Zhijing An and Chang Xu and Fang Wang and Yi Hu and Qinghui Zhuang and Xiaosong Zhong},
journal = {Research Square},
year = {2022},
doi = {10.21203/rs.3.rs-1483519/v1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell stem cell 2023
Open access · CC-BY
Advancing cell-based cancer immunotherapy through stem cell engineering
2020
Citation only
Stem Cells and Aging
Stem Cells Translational Medicine 2012
Open access · OA
Concise Review: Hematopoietic Stem Cell Aging, Life Span, and Transplantation
The Journal of Immunology 2015
Citation only
Effects of natural supplementation on human T cell longevity pathways (LYM6P.723)
Cancer Research 2005
Open access · OA
Control of Multidrug Resistance Gene mdr1 and Cancer Resistance to Chemotherapy by the Longevity Gene sirt1
Elsevier eBooks 2018
Citation only